{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:01:44Z","timestamp":1780704104105,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R01EY026174"],"award-info":[{"award-number":["R01EY026174"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["GW190010"],"award-info":[{"award-number":["GW190010"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","award":["I01 CX002015"],"award-info":[{"award-number":["I01 CX002015"]}],"id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY014801"],"award-info":[{"award-number":["P30EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jtos.2020.10.003","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:45:55Z","timestamp":1603280755000},"page":"270-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Matrix metalloproteinase 9 positivity predicts long term decreased tear production"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8695-2541","authenticated-orcid":false,"given":"Matias","family":"Soifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem M.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Stinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-6155","authenticated-orcid":false,"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-5950","authenticated-orcid":false,"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2020.10.003_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2020.10.003_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2020.10.003_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtos.2015.12.007","article-title":"Dry eye profiles in patients with a positive elevated surface matrix metalloproteinase 9 point-of-care test versus negative patients HHS public access","volume":"14","author":"Lanza","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.10.003_bib4","first-page":"2300","article-title":"Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay","volume":"vol. 123","author":"Messmer","year":"2016"},{"issue":"1","key":"10.1016\/j.jtos.2020.10.003_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","article-title":"Dry eye disease: an immune-mediated ocular surface disorder","volume":"130","author":"Stevenson","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2020.10.003_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2020.10.003_bib7","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.10.003_bib8","first-page":"475","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"vol. 121","author":"Sheppard","year":"2014"},{"issue":"1","key":"10.1016\/j.jtos.2020.10.003_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ophtha.2014.07.048","article-title":"Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease","volume":"122","author":"Aragona","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jtos.2020.10.003_bib10","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1167\/iovs.05-1382","article-title":"Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium","volume":"47","author":"Corrales","year":"2006","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.jtos.2020.10.003_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ICL.0000162759.79740.46","article-title":"Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface","volume":"31","author":"Luo","year":"2005","journal-title":"Eye Contact Lens"},{"issue":"12","key":"10.1016\/j.jtos.2020.10.003_bib12","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface","volume":"45","author":"Luo","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.jtos.2020.10.003_bib13","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1167\/iovs.08-2476","article-title":"Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome","volume":"50","author":"Chotikavanich","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2020.10.003_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/ICO.0b013e3182541e9a","article-title":"The practical detection of MMP-9 diagnoses ocular surface disease and may help prevent its complications","volume":"32","author":"Kaufman","year":"2013","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.jtos.2020.10.003_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/ICO.0000000000000175","article-title":"Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease","volume":"33","author":"Sambursky","year":"2014","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2020.10.003_bib16","first-page":"24","article-title":"Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye","volume":"131","author":"Sambursky","year":"2013","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2020.10.003_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00003226-200404000-00010","article-title":"The repeatability of clinical measurements of dry eye","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.jtos.2020.10.003_bib18","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/ICO.0b013e318242fd60","article-title":"Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management","volume":"31","author":"Sullivan","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2020.10.003_bib19","series-title":"InflammaDry [package insert]","year":"2017"},{"key":"10.1016\/j.jtos.2020.10.003_bib20","article-title":"Evaluating the functional impact of dry eye: the ocular surface disease index. e","volume":"31","author":"Walt","year":"1436","journal-title":"Drug Inf J."},{"key":"10.1016\/j.jtos.2020.10.003_bib21","first-page":"221","article-title":"Of the national eye institute\/industry workshop on clinical trials in dry eyes","volume":"21","author":"Report","year":"1995","journal-title":"CLAO J"},{"key":"10.1016\/j.jtos.2020.10.003_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/bimj.201800034","article-title":"Power calculation of adjusted McNemar's test based on clustered data of varying cluster size","volume":"60","author":"Y","year":"2018","journal-title":"Biom J"},{"issue":"3","key":"10.1016\/j.jtos.2020.10.003_bib23","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1167\/iovs.11-7627","article-title":"Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests","volume":"53","author":"Vandermeid","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2020.10.003_bib24","series-title":"Matrix metalloproteinase 9 point-of-care immunoassay result predicts response to topical cyclosporine treatment in dry eye disease","author":"Yong Park","year":"2018"},{"key":"10.1016\/j.jtos.2020.10.003_bib25","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","article-title":"Clinical outcomes of Lifitegrast 5% ophthalmic solution in the treatment of dry eye disease","volume":"46","author":"Tong","year":"2020","journal-title":"Eye Contact Lens"},{"issue":"12","key":"10.1016\/j.jtos.2020.10.003_bib26","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1167\/iovs.04-0299","article-title":"Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells","volume":"45","author":"Li","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.jtos.2020.10.003_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9440(10)62232-8","article-title":"Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye","volume":"166","author":"Pflugfelder","year":"2005","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.jtos.2020.10.003_bib28","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.4049\/jimmunol.176.7.3950","article-title":"Desiccating stress induces T cell-mediated Sj\u00f6gren\u2019s syndrome-like lacrimal keratoconjunctivitis","volume":"176","author":"Niederkorn","year":"2006","journal-title":"J Immunol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420301592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420301592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:44:27Z","timestamp":1761540267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012420301592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"alternative-id":["S1542012420301592"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2020.10.003","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matrix metalloproteinase 9 positivity predicts long term decreased tear production","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2020.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}